Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.

Eli Lilly is partnering with Imagine Entertainment and MACRO to drive industry-wide change and guide in authentically representing disease.

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now. Some might argue that it's too late for investors to get in on Eli Lilly,

Pharmaceutical giant Eli Lilly announced Wednesday that it plans to invest roughly $27 billion in United States manufacturing more than doubling its investment over the past five years. The company said this will be the largest pharmaceutical manufacturing investment in United States history.

US pharmaceutical giant Eli Lilly announced Wednesday that it will build four additional new manufacturing sites in the United States in a committment designed to influence upcoming Trump administrati

I also want to go to Eli Lilly as well, because the news this morning that they are reducing the cost of certain vials to $50 less I'm quite literally sitting in Matt Miller seat. So I have to ask you how much price pressure there is in this industry and should consumers be waiting till it's 00 less?

Eli Lilly is offering vials of its obesity drug Zepbound to patients at a discount — but only if they skip their insurance.

Aspen Pharmacare posted a 5% rise in half-year earnings on Monday and said it expects double-digit revenue and core profit growth in its commercial pharmaceuticals unit in the full year, benefiting from its Latin American portfolio and the roll-out of its weight-loss drug Mounjaro.

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy.

A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss drug Zepbound in the U.S.